Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
LQWD Technologies Lightning Network Infrastructure Surpasses 1 Million Global Transactions (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Palisade Bio Inc PALI

Healthcare Biotechnology
Palisade Bio, Inc. is a biopharmaceutical company focused on developing novel therapeutics for serious chronic gastrointestinal diseases. It is engaged in advancing a PALI-2108 for the treatment of IBD, including UC and CD and are researching PALI-1908. IBD is a chronic condition characterized by inflammation within the gastrointestinal tract. UC primarily affects the colon and the rectum. CD... see more

Recent & Breaking News (NDAQ:PALI)

Palisade Bio (Nasdaq: PALI) Reports Year End 2021 Financial Results and Corporate Update

GlobeNewswire March 18, 2022

Palisade Bio (Nasdaq: PALI) Announces Analysis Demonstrating LB1148 Reduced the Extent and Severity of Post-Surgical Intraabdominal Adhesions by 93%

GlobeNewswire March 16, 2022

Preventing Post-Surgical Abdominal Adhesions: Virtual Presentation on Palisade Bio's LB1148 Clinical Data; To Be Hosted & Moderated by Stonegate Capital Partners

Newsfile March 14, 2022

Palisade Bio (Nasdaq: PALI) to Present New Clinical Data of LB1148 for Preventing Adhesions in Conjunction with Next Big Thing Session at Society of American Gastrointestinal and Endoscopic Surgeons 2022 Annual Meeting

GlobeNewswire March 9, 2022

Palisade Bio (Nasdaq: PALI) to Present at the Biocom Global Life Science Partnering Conference

GlobeNewswire February 18, 2022

Palisade Bio (NASDAQ: PALI) Adds Pharmaceutical Industry Executive Robert McRae to Leadership Team

GlobeNewswire February 15, 2022

Palisade Bio (Nasdaq: PALI) to Announce Adhesions Clinical Data at SAGES 2022 Annual Meeting

GlobeNewswire February 8, 2022

Palisade Bio to Present at the H.C. Wainwright BIOCONNECT Virtual Conference and Biotech Showcase

GlobeNewswire December 29, 2021

Palisade Bio Granted New U.S. Patent Covering Protease Inhibitor LB1148 for Treating Adhesions and Postoperative Ileus

GlobeNewswire December 8, 2021

Palisade Bio Announces the European Patent Office to Grant a Patent for its Lead Drug Candidate LB1148, Providing Protection Through 2035

GlobeNewswire November 30, 2021

Palisade Bio Announces Inducement Awards Under Inducement Plan for Key New Hires, Including Nick McCoy, Vice President of Clinical Operations

GlobeNewswire November 23, 2021

Palisade Bio Reports Third Quarter Financial Results

GlobeNewswire November 15, 2021

Palisade Bio, Inc. Announces Sale of Seneca Asset NSI-189 for the Treatment of Central Nervous System Disorders

GlobeNewswire October 22, 2021

Palisade Bio to Present at the H.C. Wainwright 23rd Annual Global Investment Virtual Conference

GlobeNewswire September 9, 2021

Palisade Bio Reports Second Quarter Financial Results and Provides Business Update

GlobeNewswire August 24, 2021

Palisade Bio Announces $5.2M Investment by the Yuma Regional Medical Center

GlobeNewswire August 20, 2021

Seneca Biopharma Announces Successful Approval of Merger with Leading Biosciences, Inc.

PR Newswire April 26, 2021

Leading BioSciences Announces Early Efficacy Signal in Reducing Post-Surgical Adhesions in Open Label Study

GlobeNewswire April 20, 2021

Leading BioSciences Provides Update to Seneca Biopharma, Inc. Stockholders on Merger Closing Process Following Virtual Special Meeting on April 23, 2021 and Upcoming Milestones Following Planned Close of Merger

GlobeNewswire April 19, 2021

Leading BioSciences Releases Video Message Encouraging Seneca Biopharma, Inc. Stockholders to Vote at the Virtual Special Meeting on April 23, 2021

GlobeNewswire April 12, 2021